Prolonged adjuvant imatinib shows promise in localised GIST
A study reports a disease-free survival benefit with six years of maintenance therapy with imatinib compared to the 3-year standard of careÂ
A study reports a disease-free survival benefit with six years of maintenance therapy with imatinib compared to the 3-year standard of careÂ
This cross-sectional study examines the inclusion of climate- and climate change–related mitigation efforts in cancer prevention plans in US states, tribes, and territories.
Welcome to our Elsevier’s Oncology Journal Network Highlights page
The Virtual Clinical Trials Office will provide remote staffing support to assist with NCI-funded cancer clinical trials.
The Clinical Trials Innovation Unit (CTIU) is an authoritative body made up of experts from the federal government, academia, and the private sector that aims…
Reshaping cancer clinical trials will involve embracing technology, collaboration, and innovation, explain Drs. W. Kimryn Rathmell and Shaalan Beg.
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
Among patients with ALK-positive, advanced NSCLC who received lorlatinib, the median PFS was not reached at 5 years.
The OSUCCC – James will honor the millions of adults and children with a history of cancer throughout the month of June.
Deputy Editor of The ASCO Post, Jame Abraham, MD, FACP, recently spoke with gynecologic cancer expert Sharmila K. Makhija, MD, MBA, about her journey to…
Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.